Digital Therapeutics

There are dozens of software-driven products under regulatory review for diagnosing, treating, or preventing medical conditions, defining an entirely new sector for the life sciences industry.Today we are joined by Allison Murphy, Vice President, Business Development, Selling Solutions at Syneos Health and Skye Hodson, PhD, Engagement Manager, Commercial Advisory Group at Syneos Health Consulting, to discuss the digital therapeutics landscape, the opportunities for both biopharma and tech companies, regulatory and payer hurdles, and more.For a deeper dive, download our report, How Digital Therapeutics Developers Can Satisfy Diverse Stakeholder Needs.To become part of the broader conversation, check out these organizations mentioned in this episode: Digital Therapeutics Alliance and Digital Medicine Society (DiMe). Like what you’re hearing?  Be sure to rate and review us!  We want to hear from you!  If there’s a topic you’d like us to cover on a future episode, contact us at [email protected]. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.  If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub. Like what you’re hearing? Be sure to rate and review us!  We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at [email protected].